Preclinical data have shown that PD-1 inhibitors can increase antitumour immunity with TTFields89 and underpin a currently ongoing clinical trial investigating the efficacy of combining PD-1 inhibitors with TTFields for the treatment of patients with NSCLC (LUNAR NCT02973789—see Table 1). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.